Comparison · NCT00480025-7f3505db
GSK1572932 Group vs Placebo Group: Number of Patients With Serious Adverse Events (SAEs) - Up to Data Lock Point (DLP)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GSK1572932 Group vs Placebo Group: Number of Patients With Serious Adverse Events (SAEs) - Up to Data Lock Point (DLP). Trial comparisons, record NCT00480025-7f3505db. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00480025-7f3505db
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.218 | 0.198 | 0.239 | wilson | |
| Risk in group 2 | 0.217 | 0.189 | 0.247 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00118 | -0.0355 | 0.0364 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.852 | 1.19 | log | |
| Odds ratio, group 1 over group 2 | 1.01 | 0.815 | 1.24 | log | |
| Number needed to treat, for one more participant with the outcome on GSK1572932 Group than on Placebo Group | 850 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GSK1572932 Group | Patients received up to 13 doses of GSK1572932, 5 doses every 3 weeks followed by 8 doses every 12 weeks. | 330 | 1,515 | OG000 |
| Group 2 | Placebo Group | Patients received up to 13 doses of placebo, 5 doses every 3 weeks followed by 8 doses every 12 weeks. | 164 | 757 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients With Serious Adverse Events (SAEs) - Up to Data Lock Point (DLP)
- Description
A SAE is any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study subject, or was a Grade 4 AE according to CTC for Adverse Events, Version 3.0. Events part of natural course of lung cancer (i.e., disease progression, recurrence) were captured towards clinical efficacy assessment (CEA) and were not reported as SAEs. Death due to a progressive disease was similarly recorded towards CEA, but not as an SAE. However, if progression of lung cancer disease was greater than normally be expected, or if investigators considered that there was a causal relationship between treatment or protocol design/procedures and disease progression/ recurrence, then it was reported as SAE. Any new cancer (non-related to lung cancer) was reported as SAE.
- Time frame
- From screening (SCR) up to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
- Population
- The Total Treated population - as treated included patients in the treatment group as per treatment actually received.
Source ClinicalTrials.gov
Trial
- Title
- GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
- NCT number
- NCT00480025
- Phases
- PHASE3
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- GSK1572932A Antigen-Specific Cancer Immunotherapeutic, Placebo Control
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2019-01-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00480025?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00480025-7f3505db